R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.
Identifieur interne : 003539 ( PubMed/Corpus ); précédent : 003538; suivant : 003540R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.
Auteurs : John F. Seymour ; Michael Pfreundschuh ; Marek Trn N ; Laurie H. Sehn ; John Catalano ; Eva Csinady ; Nicola Moore ; Bertrand CoiffierSource :
- Haematologica [ 1592-8721 ] ; 2014.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors (administration & dosage), Antibodies, Monoclonal, Humanized (administration & dosage), Antibodies, Monoclonal, Murine-Derived (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (administration & dosage), Bevacizumab, Cyclophosphamide (administration & dosage), Doxorubicin (administration & dosage), Female, Humans, Lymphoma, Large B-Cell, Diffuse (diagnosis), Lymphoma, Large B-Cell, Diffuse (drug therapy), Male, Middle Aged, Prednisone (administration & dosage), Treatment Outcome, Vincristine (administration & dosage), Young Adult.
- MESH :
- chemical , administration & dosage : Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Murine-Derived, Cyclophosphamide, Doxorubicin, Prednisone, Vincristine.
- administration & dosage : Antineoplastic Combined Chemotherapy Protocols.
- diagnosis : Lymphoma, Large B-Cell, Diffuse.
- drug therapy : Lymphoma, Large B-Cell, Diffuse.
- Adolescent, Adult, Aged, Aged, 80 and over, Bevacizumab, Female, Humans, Male, Middle Aged, Treatment Outcome, Young Adult.
Abstract
Vascular endothelial growth factor is involved in lymphoma growth, suggesting a potential role for anti-vascular endothelial growth factor therapies in hematologic malignancies. In this phase III study, patients with CD20-positive diffuse large B-cell lymphoma were randomized to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone plus either placebo (R-CHOP) or bevacizumab (RA-CHOP). Treatment was administered every 21 (8 cycles) or 14 days (6 cycles plus 2 rituximab cycles) as per institutional practice. An early analysis of risk/benefit by the Data and Safety Monitoring Board showed that RA-CHOP increased cardiotoxicity without prolonging progression-free survival compared with R-CHOP, and the trial was stopped early. The study protocol was amended to allow for 12 additional months of follow up to evaluate safety. With 787 patients enrolled, median follow up was 23.7 and 23.6 months for R-CHOP and RA-CHOP, respectively. Median progression-free survival for R-CHOP and RA CHOP was 42.9 and 40.2 months, respectively (hazard ratio=1.09; P=0.49). The proportion of deaths was identical for R-CHOP (83 of 387, 21%) and RA-CHOP (82 of 390, 21%). Relative to R-CHOP, RA-CHOP had a higher rate of left ventricular ejection fraction perturbation (18% vs. 8%; odds ratio=2.51; 95% confidence interval (CI): 1.60-3.93) and congestive heart failure (16% vs. 7%; odds ratio=2.79; 95%CI: 1.72-4.54). Bevacizumab added to R-CHOP increased cardiac events, without increasing efficacy, arguing against further evaluation of RA-CHOP in patients with diffuse large B-cell lymphoma. The MAIN study is registered at clinicaltrials.gov identifier:00486759.
DOI: 10.3324/haematol.2013.100818
PubMed: 24895339
Links to Exploration step
pubmed:24895339Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.</title>
<author><name sortKey="Seymour, John F" sort="Seymour, John F" uniqKey="Seymour J" first="John F" last="Seymour">John F. Seymour</name>
<affiliation><nlm:affiliation>Peter MacCallum Cancer Centre, East Melbourne, Australia University of Melbourne, Parkville, Australia John.Seymour@petermac.org.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pfreundschuh, Michael" sort="Pfreundschuh, Michael" uniqKey="Pfreundschuh M" first="Michael" last="Pfreundschuh">Michael Pfreundschuh</name>
<affiliation><nlm:affiliation>Saarland University Hospital, Homburg, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Trn N, Marek" sort="Trn N, Marek" uniqKey="Trn N M" first="Marek" last="Trn N">Marek Trn N</name>
<affiliation><nlm:affiliation>General Hospital, Charles University First Faculty of Medicine, Prague, Czech Republic.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sehn, Laurie H" sort="Sehn, Laurie H" uniqKey="Sehn L" first="Laurie H" last="Sehn">Laurie H. Sehn</name>
<affiliation><nlm:affiliation>Centre for Lymphoid Cancer, British Columbia Cancer Agency, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Catalano, John" sort="Catalano, John" uniqKey="Catalano J" first="John" last="Catalano">John Catalano</name>
<affiliation><nlm:affiliation>Frankston Hospital and Monash University, Frankston, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Csinady, Eva" sort="Csinady, Eva" uniqKey="Csinady E" first="Eva" last="Csinady">Eva Csinady</name>
<affiliation><nlm:affiliation>F. Hoffmann-La Roche Ltd. Pharmaceuticals Division, PDCO, Basel, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Moore, Nicola" sort="Moore, Nicola" uniqKey="Moore N" first="Nicola" last="Moore">Nicola Moore</name>
<affiliation><nlm:affiliation>F. Hoffmann-La Roche Ltd. Pharmaceuticals, Biostatistics, Basel, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Coiffier, Bertrand" sort="Coiffier, Bertrand" uniqKey="Coiffier B" first="Bertrand" last="Coiffier">Bertrand Coiffier</name>
<affiliation><nlm:affiliation>Centre Hospitalier Lyon-Sud, Lyon, France.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24895339</idno>
<idno type="pmid">24895339</idno>
<idno type="doi">10.3324/haematol.2013.100818</idno>
<idno type="wicri:Area/PubMed/Corpus">003539</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003539</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.</title>
<author><name sortKey="Seymour, John F" sort="Seymour, John F" uniqKey="Seymour J" first="John F" last="Seymour">John F. Seymour</name>
<affiliation><nlm:affiliation>Peter MacCallum Cancer Centre, East Melbourne, Australia University of Melbourne, Parkville, Australia John.Seymour@petermac.org.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pfreundschuh, Michael" sort="Pfreundschuh, Michael" uniqKey="Pfreundschuh M" first="Michael" last="Pfreundschuh">Michael Pfreundschuh</name>
<affiliation><nlm:affiliation>Saarland University Hospital, Homburg, Germany.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Trn N, Marek" sort="Trn N, Marek" uniqKey="Trn N M" first="Marek" last="Trn N">Marek Trn N</name>
<affiliation><nlm:affiliation>General Hospital, Charles University First Faculty of Medicine, Prague, Czech Republic.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sehn, Laurie H" sort="Sehn, Laurie H" uniqKey="Sehn L" first="Laurie H" last="Sehn">Laurie H. Sehn</name>
<affiliation><nlm:affiliation>Centre for Lymphoid Cancer, British Columbia Cancer Agency, Canada.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Catalano, John" sort="Catalano, John" uniqKey="Catalano J" first="John" last="Catalano">John Catalano</name>
<affiliation><nlm:affiliation>Frankston Hospital and Monash University, Frankston, Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Csinady, Eva" sort="Csinady, Eva" uniqKey="Csinady E" first="Eva" last="Csinady">Eva Csinady</name>
<affiliation><nlm:affiliation>F. Hoffmann-La Roche Ltd. Pharmaceuticals Division, PDCO, Basel, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Moore, Nicola" sort="Moore, Nicola" uniqKey="Moore N" first="Nicola" last="Moore">Nicola Moore</name>
<affiliation><nlm:affiliation>F. Hoffmann-La Roche Ltd. Pharmaceuticals, Biostatistics, Basel, Switzerland.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Coiffier, Bertrand" sort="Coiffier, Bertrand" uniqKey="Coiffier B" first="Bertrand" last="Coiffier">Bertrand Coiffier</name>
<affiliation><nlm:affiliation>Centre Hospitalier Lyon-Sud, Lyon, France.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Haematologica</title>
<idno type="eISSN">1592-8721</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Angiogenesis Inhibitors (administration & dosage)</term>
<term>Antibodies, Monoclonal, Humanized (administration & dosage)</term>
<term>Antibodies, Monoclonal, Murine-Derived (administration & dosage)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (administration & dosage)</term>
<term>Bevacizumab</term>
<term>Cyclophosphamide (administration & dosage)</term>
<term>Doxorubicin (administration & dosage)</term>
<term>Female</term>
<term>Humans</term>
<term>Lymphoma, Large B-Cell, Diffuse (diagnosis)</term>
<term>Lymphoma, Large B-Cell, Diffuse (drug therapy)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Prednisone (administration & dosage)</term>
<term>Treatment Outcome</term>
<term>Vincristine (administration & dosage)</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Angiogenesis Inhibitors</term>
<term>Antibodies, Monoclonal, Humanized</term>
<term>Antibodies, Monoclonal, Murine-Derived</term>
<term>Cyclophosphamide</term>
<term>Doxorubicin</term>
<term>Prednisone</term>
<term>Vincristine</term>
</keywords>
<keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Lymphoma, Large B-Cell, Diffuse</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphoma, Large B-Cell, Diffuse</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Bevacizumab</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Vascular endothelial growth factor is involved in lymphoma growth, suggesting a potential role for anti-vascular endothelial growth factor therapies in hematologic malignancies. In this phase III study, patients with CD20-positive diffuse large B-cell lymphoma were randomized to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone plus either placebo (R-CHOP) or bevacizumab (RA-CHOP). Treatment was administered every 21 (8 cycles) or 14 days (6 cycles plus 2 rituximab cycles) as per institutional practice. An early analysis of risk/benefit by the Data and Safety Monitoring Board showed that RA-CHOP increased cardiotoxicity without prolonging progression-free survival compared with R-CHOP, and the trial was stopped early. The study protocol was amended to allow for 12 additional months of follow up to evaluate safety. With 787 patients enrolled, median follow up was 23.7 and 23.6 months for R-CHOP and RA-CHOP, respectively. Median progression-free survival for R-CHOP and RA CHOP was 42.9 and 40.2 months, respectively (hazard ratio=1.09; P=0.49). The proportion of deaths was identical for R-CHOP (83 of 387, 21%) and RA-CHOP (82 of 390, 21%). Relative to R-CHOP, RA-CHOP had a higher rate of left ventricular ejection fraction perturbation (18% vs. 8%; odds ratio=2.51; 95% confidence interval (CI): 1.60-3.93) and congestive heart failure (16% vs. 7%; odds ratio=2.79; 95%CI: 1.72-4.54). Bevacizumab added to R-CHOP increased cardiac events, without increasing efficacy, arguing against further evaluation of RA-CHOP in patients with diffuse large B-cell lymphoma. The MAIN study is registered at clinicaltrials.gov identifier:00486759.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24895339</PMID>
<DateCreated><Year>2014</Year>
<Month>08</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted><Year>2015</Year>
<Month>04</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1592-8721</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>99</Volume>
<Issue>8</Issue>
<PubDate><Year>2014</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Haematologica</Title>
<ISOAbbreviation>Haematologica</ISOAbbreviation>
</Journal>
<ArticleTitle>R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes.</ArticleTitle>
<Pagination><MedlinePgn>1343-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3324/haematol.2013.100818</ELocationID>
<Abstract><AbstractText>Vascular endothelial growth factor is involved in lymphoma growth, suggesting a potential role for anti-vascular endothelial growth factor therapies in hematologic malignancies. In this phase III study, patients with CD20-positive diffuse large B-cell lymphoma were randomized to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone plus either placebo (R-CHOP) or bevacizumab (RA-CHOP). Treatment was administered every 21 (8 cycles) or 14 days (6 cycles plus 2 rituximab cycles) as per institutional practice. An early analysis of risk/benefit by the Data and Safety Monitoring Board showed that RA-CHOP increased cardiotoxicity without prolonging progression-free survival compared with R-CHOP, and the trial was stopped early. The study protocol was amended to allow for 12 additional months of follow up to evaluate safety. With 787 patients enrolled, median follow up was 23.7 and 23.6 months for R-CHOP and RA-CHOP, respectively. Median progression-free survival for R-CHOP and RA CHOP was 42.9 and 40.2 months, respectively (hazard ratio=1.09; P=0.49). The proportion of deaths was identical for R-CHOP (83 of 387, 21%) and RA-CHOP (82 of 390, 21%). Relative to R-CHOP, RA-CHOP had a higher rate of left ventricular ejection fraction perturbation (18% vs. 8%; odds ratio=2.51; 95% confidence interval (CI): 1.60-3.93) and congestive heart failure (16% vs. 7%; odds ratio=2.79; 95%CI: 1.72-4.54). Bevacizumab added to R-CHOP increased cardiac events, without increasing efficacy, arguing against further evaluation of RA-CHOP in patients with diffuse large B-cell lymphoma. The MAIN study is registered at clinicaltrials.gov identifier:00486759.</AbstractText>
<CopyrightInformation>Copyright© Ferrata Storti Foundation.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seymour</LastName>
<ForeName>John F</ForeName>
<Initials>JF</Initials>
<AffiliationInfo><Affiliation>Peter MacCallum Cancer Centre, East Melbourne, Australia University of Melbourne, Parkville, Australia John.Seymour@petermac.org.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pfreundschuh</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Saarland University Hospital, Homburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Trnĕný</LastName>
<ForeName>Marek</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>General Hospital, Charles University First Faculty of Medicine, Prague, Czech Republic.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sehn</LastName>
<ForeName>Laurie H</ForeName>
<Initials>LH</Initials>
<AffiliationInfo><Affiliation>Centre for Lymphoid Cancer, British Columbia Cancer Agency, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Catalano</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Frankston Hospital and Monash University, Frankston, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Csinady</LastName>
<ForeName>Eva</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd. Pharmaceuticals Division, PDCO, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Moore</LastName>
<ForeName>Nicola</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd. Pharmaceuticals, Biostatistics, Basel, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Coiffier</LastName>
<ForeName>Bertrand</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Centre Hospitalier Lyon-Sud, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><CollectiveName>MAIN Study Investigators</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT00486759</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>06</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Italy</Country>
<MedlineTA>Haematologica</MedlineTA>
<NlmUniqueID>0417435</NlmUniqueID>
<ISSNLinking>0390-6078</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058846">Antibodies, Monoclonal, Murine-Derived</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C571759">R-CHOP protocol</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2S9ZZM9Q9V</RegistryNumber>
<NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>5J49Q6B70F</RegistryNumber>
<NameOfSubstance UI="D014750">Vincristine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>80168379AG</RegistryNumber>
<NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>8N3DW7272P</RegistryNumber>
<NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>VB0R961HZT</RegistryNumber>
<NameOfSubstance UI="D011241">Prednisone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Lab Invest. 2008 Jan;88(1):38-47</RefSource>
<PMID Version="1">17998899</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2007 Apr 20;25(12):1539-44</RefSource>
<PMID Version="1">17442997</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2008 Feb;9(2):105-16</RefSource>
<PMID Version="1">18226581</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2008 Nov 27;359(22):2313-23</RefSource>
<PMID Version="1">19038878</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Mar 10;27(8):1227-34</RefSource>
<PMID Version="1">19188680</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Leuk Lymphoma. 2009 Mar;50(3):366-73</RefSource>
<PMID Version="1">19347725</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Leuk Lymphoma. 2009 May;50(5):728-35</RefSource>
<PMID Version="1">19373598</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Immunol Ther Exp (Warsz). 2009 Nov-Dec;57(6):435-45</RefSource>
<PMID Version="1">19866340</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2010 Mar;46(5):974-82</RefSource>
<PMID Version="1">20064707</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2011 Feb 20;29(6):632-8</RefSource>
<PMID Version="1">21205755</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2011 Jul;96(7):996-1001</RefSource>
<PMID Version="1">21546504</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hypertens Res. 2012 Feb;35(2):194-200</RefSource>
<PMID Version="1">22089532</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Mol Cell Cardiol. 2012 May;52(5):1164-75</RefSource>
<PMID Version="1">22326847</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Blood. 2012 Aug 9;120(6):1210-7</RefSource>
<PMID Version="1">22734071</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2012 Dec;13(12):1250-9</RefSource>
<PMID Version="1">23168367</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2000 Mar 2;342(9):626-33</RefSource>
<PMID Version="1">10699162</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2002 Jan 24;346(4):235-42</RefSource>
<PMID Version="1">11807147</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Anticancer Res. 2002 Sep-Oct;22(5):2899-901</RefSource>
<PMID Version="1">12530014</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2003 Feb;14(2):277-81</RefSource>
<PMID Version="1">12562656</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Physiol Heart Circ Physiol. 2003 Dec;285(6):H2420-9</RefSource>
<PMID Version="1">12881220</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2004 Jun 3;350(23):2335-42</RefSource>
<PMID Version="1">15175435</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Blood. 2004 Nov 1;104(9):2893-902</RefSource>
<PMID Version="1">15238424</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 1973 Aug;32(2):302-14</RefSource>
<PMID Version="1">4353012</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 1979 Nov;91(5):710-7</RefSource>
<PMID Version="1">496103</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1993 Sep 30;329(14):987-94</RefSource>
<PMID Version="1">8141877</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Pathol. 1997 Sep;183(1):44-50</RefSource>
<PMID Version="1">9370946</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2005 Jun 20;23(18):4117-26</RefSource>
<PMID Version="1">15867204</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2005 Aug 1;23(22):5027-33</RefSource>
<PMID Version="1">15955905</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2006 May;7(5):379-91</RefSource>
<PMID Version="1">16648042</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2006 Jul 1;24(19):3121-7</RefSource>
<PMID Version="1">16754935</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Leuk Lymphoma. 2006 Jun;47(6):998-1005</RefSource>
<PMID Version="1">16840188</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2006 Oct;20(10):1759-66</RefSource>
<PMID Version="1">16932349</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2006 Dec 14;355(24):2542-50</RefSource>
<PMID Version="1">17167137</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Physiol Heart Circ Physiol. 2007 Jan;292(1):H333-41</RefSource>
<PMID Version="1">16951052</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2007 Feb 10;25(5):579-86</RefSource>
<PMID Version="1">17242396</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Pathol. 2007 Apr;170(4):1362-9</RefSource>
<PMID Version="1">17392174</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cancer Res Clin Oncol. 2008 Mar;134(3):381-7</RefSource>
<PMID Version="1">17694324</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058846" MajorTopicYN="N">Antibodies, Monoclonal, Murine-Derived</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000068258" MajorTopicYN="N">Bevacizumab</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016403" MajorTopicYN="N">Lymphoma, Large B-Cell, Diffuse</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014750" MajorTopicYN="N">Vincristine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4116833</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>6</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>6</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>4</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24895339</ArticleId>
<ArticleId IdType="pii">haematol.2013.100818</ArticleId>
<ArticleId IdType="doi">10.3324/haematol.2013.100818</ArticleId>
<ArticleId IdType="pmc">PMC4116833</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003539 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003539 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:24895339 |texte= R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24895339" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |